Sanofi Confident In Beyfortus Achieving Blockbuster Status In 2024

Foresees Strength Versus Future RSV Antibody Competitor

Jul 25 2024

Beyfortus and Dupixent bookended Sanofi's sales in terms of lowest and highest sellers in Q2 • Source: Shutterstock